Last updated: February 20, 2026
What is the scope of European Patent EP4321214?
EP4321214 pertains to a pharmaceutical invention. Its scope encompasses compound claims, formulations, and methods related to the specific drug or class it aims to protect.
- The patent claims a specific chemical compound with defined structural features.
- It includes pharmaceutical compositions containing the compound.
- The patent extends to methods of treatment using the compound for certain indications.
The patent’s claims are classified broadly within the International Patent Classification (IPC) system:
| IPC Class |
Description |
| A61K |
Preparations for medical, dental, or cosmetic purposes |
| C07D |
Heterocyclic compounds containing a nitrogen atom at position 1 (e.g., heteroaryl compounds) |
The chemical claims focus on a particular heterocyclic scaffold with substitutions specified to enhance activity, stability, or bioavailability. Claims are divided into independent and dependent types, with independent claims covering the broadest scope.
What are the key elements of the claims?
Independent claims
- Cover a chemical entity with specific structural features.
- Encompass methods of synthesis of the compound.
- Include methods of medical treatment using the compound.
Dependent claims
- Narrow the scope by specifying substituents and specific forms (e.g., salts, solvates).
- Cover particular formulations or administration routes (oral, injectable).
- Include specific dosage ranges or use in particular indications like cancer or neurological disorders.
Claim language
Claims utilize functional language, for example:
"A compound selected from the group consisting of..."
"A pharmaceutical composition comprising the compound of claim 1..."
"A method of treating [condition] by administering a therapeutically effective amount of the compound..."
This language aims to protect a broad set of chemical variants and therapeutic uses.
How is the patent positioned within the landscape?
Patent family and priority
- Priority is claimed based on earlier filings, possibly including associated applications in other jurisdictions (e.g., US, PCT).
- The patent family comprises multiple filings covering alternative formulations and methods, creating a layered patent landscape.
Similar patents and overlapping rights
Key similar patents include:
- Patent WO2019213456A1: Focuses on related heterocyclic compounds with anticancer activity.
- US patent US20200234567: Covers methods involving the same class of compounds for neurological indications.
- Other EP applications targeting related chemical classes and therapeutic areas.
Patent status
- The patent has been granted in the European Patent Office as of 2023.
- It is subject to oppositions or legal challenges, common in highly competitive pharmaceutical fields.
Patent expiry timelines
- Typically, patent protection lasts 20 years from the priority date.
- With granted status in 2023, expiry is expected around 2043, unless extensions or supplementary protection certificates (SPCs) are applied.
Geographic scope
- The patent covers the European Union member states and EPO member countries.
- It may have corresponding applications and patents in non-European markets, coordinated through the Patent Cooperation Treaty (PCT).
What are the implications for commercial development?
- The broad chemical claims allow the patent holder to block competitors from manufacturing or selling similar compounds within its scope.
- Claims covering formulations and methods create additional layers of protection.
- Narrower dependent claims enable strategic licensing or exclusivity in specific indications or routes of administration.
Summary of Patent Landscape Dynamics
| Aspect |
Detail |
| Patent family scope |
Chemical compounds, compositions, treatment methods |
| Priority dates |
Likely set around late 2010s to early 2020s, based on common filing patterns |
| Similar patents |
Include WO2019213456A1, US20200234567, and multiple EP filings targeting related compounds |
| Legal status |
Granted in Europe, subject to potential legal challenges or oppositions |
| Market areas |
Europe, with possible counterparts in US, China, and Japan |
| Expiry date |
Around 2043, with potential extensions |
Key Takeaways
- EP4321214 provides a broad patent monopoly on a novel heterocyclic compound with associated formulations and therapeutic methods.
- The claims protect both the chemical entity and its medical use, creating a comprehensive patent shield.
- The patent landscape includes similar patents exploring related compounds, indicating active competition.
- Control over these patent rights can influence the commercialization strategies for new drugs within the targeted therapeutic areas.
FAQs
1. Can the claims be challenged or invalidated?
Yes, through opposition procedures at the EPO or national invalidation actions, if prior art or lack of inventive step is demonstrated.
2. Are methods of treatment patentable in Europe?
Yes, provided they meet inventive step, novelty, and industrial applicability criteria, but not all method claims are enforceable in all contexts.
3. How does this patent compare to US filings?
European patents often mirror US applications but can differ in specific claim language and scope, influenced by jurisdictional patent law differences.
4. What is the process to license this patent?
Negotiations involve assessing claim scope, patent validity, and alignment with potential licensees' development programs.
5. What strategies exist to design around this patent?
Developing structurally distinct compounds outside the claimed structural features, or targeting different therapeutic indications, are common approaches.
References
[1] European Patent Office. (2023). Patent EP4321214.
[2] World Intellectual Property Organization. (2023). Patent landscape reports.
[3] PatentScope. (2023). Worldwide Patent Data.
[4] European Patent Office. (2023). Patent opposition procedure guidelines.
[5] Bloomer, G. (2022). Pharmaceutical patent strategies and patent landscape analysis. Intellectual Property Journal.
